Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Optimum risk stratification in early-stage
endometrial cancer
combines clinicopathologic factors and the molecular
endometrial cancer
classification defined by The Cancer Genome Atlas (TCGA). It is unclear whether analysis of intratumoral immune infiltrate improves this. We developed a machine-learning, image-based algorithm to quantify density of CD8
+
and CD103
+
immune cells in tumor epithelium and stroma in 695 stage I endometrioid endometrial cancers from the PORTEC-1 and -2 trials. The relationship between immune cell density and clinicopathologic/molecular factors was analyzed by hierarchical clustering and multiple regression. The prognostic value of immune infiltrate by cell type and location was analyzed by univariable and multivariable Cox regression, incorporating the molecular
endometrial cancer
classification. Tumor-infiltrating immune cell density varied substantially between cases, and more modestly by immune cell type and location. Clustering revealed three groups with high, intermediate, and low densities, with highly significant variation in the proportion of molecular
endometrial cancer
subgroups between them. Univariable analysis revealed intraepithelial CD8
+
cell density as the strongest predictor of
endometrial cancer
recurrence; multivariable analysis confirmed this was independent of pathologic factors and molecular subgroup. Exploratory analysis suggested this association was not uniform across molecular subgroups, but greatest in tumors with
mutant p53
and absent in DNA mismatch repair-deficient cancers. Thus, this work identified that quantification of intraepithelial CD8
+
cells improved upon the prognostic utility of the molecular
endometrial cancer
classification in early-stage
endometrial cancer
.
...
PMID:Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. 3299 3
<< Previous
1
2
3